Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by bluebird bio, Inc.
< Previous
1
2
Next >
bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
August 14, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces Second Quarter 2024 Results Call Date
August 12, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Appoints O. James Sterling as Chief Financial Officer
May 29, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
May 09, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events
May 06, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene Therapy
May 06, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces Receipt of Expected Notice from Nasdaq
April 26, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
March 26, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
March 25, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
March 18, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
March 11, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook
January 08, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
December 19, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
December 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
December 10, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
December 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
December 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
November 07, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
October 30, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
October 24, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces September Investor Events
September 05, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
August 16, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
August 08, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
July 25, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.